As the first and only gene therapy created to target a critical ALS pathogenesis by lowering the quantities of SOD1 mutant proteins in motor neurons, tofersen marks a revolutionary achievement. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.